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Abstract: Mantle cell lymphoma (MCL) is a rare but aggressive B-cell hemopathy characterized by
the translocation t(11;14)(q13;q32) that leads to the overexpression of the cell cycle regulatory protein
cyclin D1. This translocation is the initial event of the lymphomagenesis, but tumor cells can acquire
additional alterations allowing the progression of the disease with a more aggressive phenotype and
a tight dependency on microenvironment signaling. To date, the chemotherapeutic-based standard
care is largely inefficient and despite the recent advent of different targeted therapies including
proteasome inhibitors, immunomodulatory drugs, tyrosine kinase inhibitors, relapses are frequent
and are generally related to a dismal prognosis. As a result, MCL remains an incurable disease. In this
review, we will present the molecular mechanisms of drug resistance learned from both preclinical
and clinical experiences in MCL, detailing the main tumor intrinsic processes and signaling pathways
associated to therapeutic drug escape. We will also discuss the possibility to counteract the acquisition
of drug refractoriness through the design of more efficient strategies, with an emphasis on the most
recent combination approaches.
Keywords: B-cell lymphoma; cyclin D1; proteasome inhibitor; ibrutinib; NF-kB pathway; mutation;
innate resistance; acquired resistance; combinatory treatment; therapeutic strategy
1. Physiopathology of Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is a rare B-cell lymphoma that represents 5–10% of all non-Hodgkin
lymphomas (NHLs), with an incidence of 0.8 cases per 100,000 persons [1]. It develops primarily
among elderly individuals with a median age of approximately 67 years and a male-to-female
ratio of 2–3:1. At diagnosis, 70% of patients or more have disseminated disease (stage III or IV),
with lymphadenopathy (75%), hepato-splenomegaly (35–60%), bone marrow (>60%) and peripheral
blood (13–77%) involvement [2]. Waldeyer’s ring and extranodal sites including the gastrointestinal
tract, are also frequently involved [3]. The clinical evolution is usually very aggressive, and despite
overall response rates above 70% with standard immunochemotherapeutic schemes (see Section 1.3),
few patients can be cured [4].
1.1. MCL Subtypes
MCL has been recognized as an aggressive small B-cell lymphoma that developed in a linear
fashion from naive B-cells. Paradoxically, a subset of patients follows an indolent clinical evolution
with a stable disease, and a longer survival, even in the absence of chemotherapy [5], reflecting, in part,
that MCL develops along two different pathways. Classical MCL (cMCL) is usually composed of
IGHV-unmutated or minimally mutated B-cells that express SOX11 (SRY (sex determining region
Y)-box 11), features genetic instability and typically involves lymph nodes and other extranodal
Cancers 2020, 12, 1565; doi:10.3390/cancers12061565 www.mdpi.com/journal/cancers
Cancers 2020, 12, 1565 2 of 27
sites. Acquisition of additional molecular/cytogenetic abnormalities can lead to even more aggressive,
blastoid or pleomorphic MCL. Leukemic non-nodal MCL (nnMCL) develops from IGHV-mutated
SOX11−B cells, carrying epigenetic imprints of germinal center (GC)-experienced B cells. It usually
involves peripheral blood, bone marrow, and often spleen. These cases feature genetic stability
and are frequently clinically indolent; however, secondary abnormalities, often involving TP53,
may occur and lead to a very aggressive disease. A third MCL subtype, in situ mantle cell neoplasia
(ISMCN), is characterized by the presence of cyclin D1+ cells; most typically in the inner zone of the
follicles. Although disseminated, this subtype appears to have a low rate of progression (Figure 1) [3].
Morphologically, three main subtypes of MCL are recognized: the classic, the blastic/blastoid, and the
pleomorphic variants. The last two subtypes have higher proliferation rates and are associated with
inferior clinical outcome [5].
Figure 1. Hypothetical models of major mantle cell lymphoma (MCL) subtypes. Precursor B cells
may colonize the inner portion of the mantle zone, representing in situ mantle cell neoplasia (ISMCN).
After the introduction of additional genetic and molecular abnormalities, ISMCN may progress,
involving or not the transit through the germinal center (GC), to classical MCL or leukemic non-nodal
MCL, respectively. More frequently, classical MCL but also leukemic non-nodal MCL undergo
additional molecular/cytogenetic abnormalities leading to clinical and sometimes to morphological
progression. Adapted from Swerdlow et al. [6].
1.2. MCL Biological Features and Prognostic Factors
The phenotype of MCL is relatively characteristic with high expression of IgM/IgD surface
immunoglobulins. Immunophenotyping reveals that neoplastic cells are usually CD5+ and CD43+
and express the B-cell-associated antigens CD19, CD20, CD22, and CD79. They are usually negative
for CD3, CD23, CD11c, CD10, and CD200. MCL cells are generally B-cell lymphoma (BCL)-2 positive
and BCL-6 negative [7]. Demonstration of t(11;14)(q13;q32) by FISH or cyclin D1 overexpression by
immunohistochemistry is generally required to diagnose MCL, although a small number of cases
are cyclin D1−. These cases have a high expression of cyclin D2 or cyclin D3; however, this is not
helpful for diagnostics as these proteins are also overexpressed in other B-cell neoplasms. The nuclear
SOX11 expression is a highly specific marker for both cyclin D1+/−MCL [8]. SOX11 is a transcription
factor that has been reported to block terminal B-cell differentiation by regulating PAX5 expression
in aggressive MCL. There is also data demonstrating a role for SOX11 as a driver of pro-angiogenic
signals in MCL through the regulation of platelet-derived growth factor A, contributing to a more
aggressive phenotype [9].
A specific MCL international prognostic index (MIPI) classifies MCL patients into low, intermediate,
and high-risk groups, based on four independent prognostic factors: age, Eastern Cooperative Oncology
Group (ECOG) performance status, lactate dehydrogenase (LDH), and leukocyte count [10,11].
Other factors such as proliferation of the tumor, karyotypic complexity, genetic aberrations, and DNA
methylation are independent prognostic factors for MCL outcome [12].
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1.3. MCL Therapy
Some newly diagnosed MCL patients can be diligently observed, deferring therapy to a later
date. Asymptomatic, low tumor burden MCL cases with non-nodal presentation and genetic stability
are candidates for this strategy [13]. Delayed treatment in these patients does not adversely affect
overall survival (OS) from time of treatment initiation [14]. Although the monoclonal antibody (mAb)
anti-CD20 rituximab is considered a standard of care for all newly diagnosed MCL patients, for patients
requiring frontline therapy, the initial therapeutic decision is dictated by the age and the fitness of the
patient. Since the 1990s, a standard regimen of cyclophosphamide, hydroxydaunomycin (doxorubicin),
vincristine, and prednisone (CHOP) has been frequently used to treat MCL patients. Response rates
associated with CHOP in this disease are rarely complete or durable, compared with those observed in
other B-cell aggressive lymphomas. Therefore, more-intensive strategies have been explored, combining
additional agents to improve both the response rates and the durations of response. Induction regimens
have included rituximab and high-dose cytarabine (araC) (an antimetabolite pyrimidine analogue),
usually followed by autologous stem cell transplantation (ASCT) in younger patients (see below) [15].
The addition of rituximab to CHOP (R-CHOP) was further established as a standard-of-care regimen
for the treatment of naive MCL patients. This regimen is now typically administered to patients who
are elderly and considered intermediate to high risk, as well as those with relapsed or refractory
(R/R) disease, and has been associated with improved OS [16]. However, median survival remains
around 5 years, and it is not yet entirely clear how the improved outcomes observed in clinical trial
have translated to real-world settings. For patients that achieve remission, consolidation therapy is
recommended [17]. For older, less-fit patients there is no generally accepted frontline therapy. R-CHOP
regimen followed by rituximab maintenance achieved a significant improvement of OS, with a 4-year
survival rate of 87%, largely superior to the 63% survival obtained with interferon (IFN)α therapy [18].
In transplant-ineligible patients with untreated, newly diagnosed MCL, a phase 3 trial
demonstrated that frontline bortezomib plus rituximab, cyclophosphamide, doxorubicin,
and prednisone (VR-CAP regimen) was associated with a survival benefit over R-CHOP, with a
median OS of 90.7 months, significantly longer that the value observed in the R-CHOP group
(55.7 months). Therefore, this approach should be considered as a standard of care in this subgroup of
patients [19].
Maintenance therapy with rituximab after R-CHOP-based induction has demonstrated clear
survival benefit in MCL patients, therefore it represents a well-established approach for postponing
disease progression. Among novel agents, the thalidomide-derivative, immunomodulatory drug
(IMiD), lenalidomide (Revlimid), has not demonstrated benefit when used as maintenance therapies in
MCL, while the first-in-class Bruton’s tyrosine kinase (BTK) inhibitor, ibrutinib (Imbruvica®) is still
under investigation in these settings (see Section 2.4) [17].
While ASCT is preferentially used in youngest/fit cases as first-line consolidation treatment and
almost never employed in the real-cohort patients in R/R MCL [20], allogeneic stem cell transplantation
(alloSCT) produces long-term disease-free remissions for around 30–40% patients, especially in younger
patients with early relapse or MCL refractory to induction therapy. This approach is considered the
sole potentially curative therapy for R/R MCL [21]. In front-line settings, alloSCT was demonstrated
to be feasible but should only be considered for patients at high risk of early progression following
conventional therapy [22].
Due to the limitations of stem cell transplantation and also considering the relatively poor
outcomes associated with chemotherapy, the potential for several chemotherapy-free strategies
has been evaluated in MCL patients since early 2000s. Consequently, a growing number of
biologically-targeted therapies are profoundly altering the landscape of MCL treatment options
in both first-line and relapsed settings [17]. Among these agents, there are currently four drugs licensed
across the world: the proteasome inhibitor bortezomib (BTZ, Velcade®), the mechanistic target of
rapamycin (mTOR) inhibitor temsirolimus (Torisel®), lenalidomide, and ibrutinib. As single agents,
overall response rates (ORRs) are 33% (8% complete response (CR)), 22% (2% CR), 28% (8% CR),
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and 68% (21% CR), respectively [23–26]. Beside this clinical efficacy, major differences have been
observed in the degree and frequency of adverse events (AEs) associated to these agents in MCL
patients. In bortezomib-receiving patients, the most commonly reported AEs are asthenia (72%),
peripheral neuropathies (55%), constipation (50%), diarrhea (47%), nausea (44%), and anorexia (39%),
the apparition of neuropathy being the most common toxicity, leading to discontinuation and eventually
to death [27]. In the case of temsirolimus, hematological toxicity (thrombocytopenia, 72–100%; anemia,
52–66%; neutropenia, 24–77%) is the most frequent AE observed in the clinical setting, and can be
generally successfully managed by dose reductions or treatment delay [28]. Hematologic toxicity was
also the most common AE observed in R/R MCL patients receiving lenalidomide, with neutropenia and
thrombocytopenia observed in 40–62% or 28–12% of the cases, depending on the cohort. Importantly,
these effects did not culminate into serious events in any studies, all hematological toxicities being
manageable and reversible upon discontinuation of the IMiD [29]. Finally, ibrutinib is by far the safest
agent among this list, with hematologic AEs limited to thrombocytopenia (22%), neutropenia (19%),
and anemia (18%). Other common AEs including diarrhea (54%), fatigue (50%), nausea (33%), dyspnea
(32%), and infection (<10%) were mostly observed during the first 6 months of therapy and with less
frequency, thus confirming the safety profile of ibrutinib in R/R MCL [30].
Several novel agents using different target points have also been used with some reported efficacy
in R/R MCL. Among the most exciting recent advances in the management of B-cell malignancies,
has been the development of chimeric antigen receptor (CAR) T cells [31]. In a recent phase 2
study involving MCL patients who did not respond to BTK inhibitor therapy, the anti-CD19 CAR
T-cell therapy, KTE-X19, achieved durable remission in patients with R/R MCL (93% ORR, 67%
CR, with progression-free survival (PFS) of 61% and OS of 83% at 1 year) but not without risks:
many study participants experienced high-grade cytopenias, infections, and neurologic events [32].
Cyclin-dependent kinase (CDK)4/6 inhibitors (e.g., abemaciclib, palbociclib) are also an attractive
therapeutic option given the role of cell-cycle deregulation in the pathogenesis of MCL [33]. Anti-CD20
mAbs, such as ofatumumab [34] and obinutuzumab, [35] have single-agent activity in rituximab-treated
patients and are good candidates to be used in combination with other therapies (see Section 4.2).
Moreover, BH3 mimetic-type BCL2 inhibitors such as ABT-199 (venetoclax), phosphatidylinositol
3-kinase (PI3K)δ inhibitors such as idelalisib, histone deacetylase (HDAC) inhibitors (e.g., vorinostat,
abexinostat or panobinostat), mTOR inhibitors (e.g., everolimus), or other small molecules including
some second-generation BTK inhibitors, are being developed and explored in MCL [36–40]. Finally,
the promising activity of anti-CD38 mAb, such as daratumumab in multiple myeloma, has prompted
the initiation of studies in other B-cell malignancies, including MCL [41].
2. Molecular Signatures of MCL
2.1. Translocation t(11;14)(q13;q32)
Such as for other aggressive lymphomas, the genomic landscape of MCL shows large variations
among patients [42,43]. However, in the vast majority of the cases, tumor cells are characterized by
the translocation t(11;14)(q13;q32) which juxtaposes the CCND1 gene encoding cyclin D1 with an
enhancer of the Ig heavy chain (IGH) gene [5]. This translocation leads to the expression of cyclin
D1 that is physiologically never expressed in the B-cell lineage. Associated with its specific kinases,
CDK4/6, cyclin D1 phosphorylates and inhibits the retinoblastoma protein (RB1), allowing the release of
transcription factors of the E2F family, the transcriptional activation of genes controlling DNA synthesis,
and the G1-to-S phase progression within the cell cycle [44]. Consistent with this cell cycle regulatory
function, tumor cells overexpressing cyclin D1 display an uncontrolled proliferation. An elevated
cyclin D1 expression and in turn, a proliferation signature, are associated with chemoresistance and a
reduced MCL patients survival [45]. Cyclin D1 expression is required for MCL cells survival since
siRNAs targeting CCND1 lead to enhanced apoptosis [46] and sensitivity towards drugs [47].
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The translocation t(11;14) is considered as the primary oncogenic event but secondary genomic
alterations including somatic mutations are necessary for the progression of the disease and contribute
to its heterogeneity [5].
2.2. Recurrent Genomic Mutations
With the use of recent technologies such as next generation sequencing (NGS) technology,
whole-genome sequencing (WGS), whole-exome sequencing (WES), and RNA expression profiling,
recurrent genomic mutations associated with MCL have been described. Although, the percentage of
mutations varies among the cohorts, the most represented abnormalities concern ataxia-telangectasia
mutated (ATM), CCND1, and TP53 (encoding the tumor suppressor p53) genes (Table 1). Mutations
of ATM affect the functional domains of the tumor suppressor protein that signals DNA damage,
whereas mutations of CCND1 are found predominantly in the exon 1, leading to the stabilization of
the protein [46]. These mutations are differentially distributed among MCL subtypes according to the
IGVH and SOX11 status. Although both are described as oncogenic drivers, they have no prognostic
values [48]. The role of ATM in MCL is still debated [49]. In sharp contrast, TP53 mutations identify a
distinct and aggressive form of MCL patients with poor or low response to upfront treatments [50,51]
and a shorter OS [48]. NOTCH1 mutations are also associated with a poor OS [52]. The other
characterized mutations target anti-apoptotic genes (BIRC3, TLR3), cell cycle regulatory genes (RB1),
genes coding for chromatin-modifier enzymes (MLL2, MLL3, WHSC1, and MEF2B) (Table 1).
Table 1. Recurrent genomic alterations described for MCL patients and cell lines.
Gene Frequency (Range) * Protein Function References
ATM 38–50% DNA repairDNA damage response [42,43,48,49,53,54]
CCND1 16–35% Cell cycle regulation [42,43,48,52–54]
TP53 14–31% DNA damage responseCell cycle regulation [42,43,48,49,53,54]
MLL2 14–20% Epigenetic regulator (HMT) [42,43]
MLL3 16% Epigenetic regulator (HMT) [42,54]
WHSC1 7–31% Epigenetic regulator (HMT) [42,43,54]
BIRC3 6–9% Apoptosis regulator through TRAF2 [42,43,54]
NOTCH1 5–16% NOTCH survival pathway [42,43,52–54]
NOTCH2 5–6% NOTCH survival pathway [42,48]
TRAF2 7% NF-κB pathway [54]
UBR5 7–18% Proteasome degradation(E3 ligase) [42,53,54]
RB1 nd Cell cycle regulation [42]
SMARCA4 nd Chromatin modifier [42]
CARD11 5% NF-κB pathway [55]
Abbreviation: nd, not defined; HMT, histone methyl-transferase. * For the various cohorts, the range of percentages
of genomic alterations is indicated with the corresponding references. Somatic mutations lead to the constitutive
activation of signaling pathway downstream of the mutated protein. Point mutation of BTK (BTKC481S) leads to
the chronic activation of BCR/NF-κB signaling and AKT pathway [56,57]. BIRC3 and TRAF2 mutations as well
as CARD11 mutation are associated with the chronic activation of the canonical NF-κB pathway [55]. NOTCH1
mutations are located in an exon coding for the PEST sequence, causing truncation of the C-terminal part of
the protein, and chronic activation of the NOTCH pathway [52]. ATM mutation sustains defects of DNA repair
machinery and impairs apoptosis [58]. p53 and ATM are interrelated, both being involved in the sensing of DNA
damage and in the balance cell cycle/apoptosis. In agreement, MCL tumor cells display a high chromosome
instability and numerous chromosome alterations [59].
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The comparison of mutations across lymphomas shows that CCND1, RB1 are found mutated
exclusively in MCL, whereas WHSC1, ATM, and BIRC3, although prominently altered in MCL, are also
found mutated in other B-cell lymphomas [42]. As a consequence of this mutational landscape, MCL
cells are highly dependent on cell cycle (CCND1, RB1), DNA damage response (ATM, TP53), and NF-κB
pathways for their survival, allowing the identification of several putative therapeutic targets among
these signaling axes.
2.3. Deletions of INK4A/ARF (CDKN2A) Locus
Several studies have investigated the global chromosomal alterations in MCL by comparative
genomic hybridization (CGH) array and single nucleotide polymorphism (SNP) array. Frequent
alterations in MCL include gain of chromosomes 3q, 7q, and 8q as well as loss of chromosomes 1p,
6q, 8p, 9p, 9q, 11q, and 17p [59–61]. The region 9p21 contains the CDKN2A locus that codes for two
tumor suppressors, p16INK4A and p14ARF. p16INKA is the physiological inhibitor of cyclin D1/CDK4/6
complexes whereas p14ARF interacts and sequesters murine double minute 2 (MDM2, the E3 ubiquitin
ligase of p53), controlling its degradation through the ubiquitin-proteasome system (UPS). Deletion
of this locus is observed in 20% of MCL patients and associated with a proliferation signature [45].
Interestingly, CDKN2A can be silenced by BMI1, a polycomb family protein which is overexpressed in
some cases [62]. Beside CDKN2A loss, the methylation of CDKN2A and CDKN2B promoters, that leads
to the transcriptional repression of these genes, has been described in a subset of MCL patients [60].
Quantitative multiplex PCR analyses confirmed the loss of CDKN2A (31% of cases) and RB1, ATM
and TP53 in 38%, 24%, and 10% of the cases, respectively; TP53 loss correlated with an unfavorable
outcome [63].
2.4. Abnormalities of Signaling Pathways
Somatic mutations described in MCL cells lead to the constitutive activation of various signaling
pathways. While deregulated p16INK4A/CDK4/RB1 and p14ARF/MDM2/p53 axes are the most common
hallmarks of MCL, several signaling pathways may be overactivated by the chronic activation of
cytokine/interleukin (IL) receptors, and/or cell/cell or cell/extracellular matrix interactions promoted by
an MCL-specific tumor microenvironment (TME).
2.4.1. B-Cell Receptor Signaling
The B-cell receptor (BCR) consists of Ig chains bound to CD79a/b co-receptors (Figure 2).
Upon binding of cognate antigen by the hypervariable regions of the BCR, the LYN tyrosine kinase
phosphorylates the intracellular domain of CD79a/b chains (ITAMs) that are then able to recruit the
spleen tyrosine kinase, SYK. Once recruited, SYK undergoes a phosphorylation at Tyr-130 residue
and consequently activates kinases and adaptor proteins to form the signalosome. The signalosome,
which include BTK, activates several downstream pathways governing crucial intracellular events like
gene transcription, mRNA translation, cell proliferation, and survival (Figure 2) [64]. Mechanistically,
once the signalosome is formed, activated BTK phosphorylates phospholipase (PL)Cγ2 which in
turn phosphorylates protein kinase C (PKC)β and caspase recruitment domain-containing protein 11
(CARD11), a key regulator of NF-κB signaling (Figure 3). The transmembrane protein CD19 is also
phosphorylated by LYN after BCR triggering and recruits phosphatidylinositol 3-kinase (PI3K) to the
BCR. PI3K regulates the phosphorylation of PIP2 (phosphatidylinositol 4,5-biphosphate) to generate
PIP3 (phosphatidylinositol 3,4,5-triphosphate). This latest has the capacity to recruit downstream
proteins like AKT and BTK at the inner plasma membrane. In turn, AKT is efficiently activated and
BTK activity is amplified. Following these events, activated PLCγ2 hydrolyzes PIP2 in diacylglycerol
(DAG) and inositol triphosphate (IP3), this latest being involved in the control of intracellular calcium
flux, which indirectly activates the nuclear factor of activated T-cells (NFAT). PLCγ2 also promotes
the activating phosphorylation of ERK (extracellular signal-regulated kinase) 1/2 (Figure 2) and,
to some extent, contributes to the regulation of JNK (Jun NH2-terminal kinase) and p38 MAPK
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(mitogen-activated protein kinase) pathways (not schematized). As a whole, BCR signaling culminates
in the activation of NF-κB, MAPK, PI3K, NFAT pathways, which all promote the proliferation and the
survival of B cells.
Figure 2. B-cell receptor signal transduction. After antigen ligation, LYN, SYK, and Bruton’s tyrosine
kinase (BTK) are activated. B-cell adaptors such as B-cell linker (BLNK) fine-tune B-cell receptor
(BCR) signals by efficiently connecting the kinases with the effectors. Activation of phospholipase
(PL)Cγ2 leads to the release of intracellular Ca2+ and activation of protein kinase C (PKC); both of
which are crucial for the activation of mitogen-activated protein kinase (MAPK), such as extracellular
signal-regulated kinase (ERK) and transcription factors, including NF-κB and NFAT. BCR signaling can
be efficiently targeted in MCL either by irreversible BTK inhibitors like the first-in-class ibrutinib and
the second generation drug, acalabrutinib, or by means of the PI3Kδ inhibitor, idelalisib. Downstream
mTOR kinase activity can be controlled by the mTORC1-targeting agents, everolimus and temsirolimus.
Adapted from Herrera et al. [65].
MCL is characterized by a highly distinctive Ig gene repertory and a biased BCR, suggesting a
crucial role for antigenic selection in the pathogenesis of at least a subset of MCL [66]. Indeed, increased
BTK autophosphorylation at Y223 has been observed in unstimulated primary MCL cells, together
with a high expression of the kinase [67]. A pro-survival role of BCR signaling is suggested by the
constitutive phosphorylation of different kinases of this pathway, including LYN, SYK, and PKCβ,
observed in a limited panel of patients [68,69]. MCL cells also harbor a constitutive activation of
NF-κB and AKT, which might reflect both BCR or toll-like receptor (TLR) constitutive activation [5,70].
Early studies in relapsed setting showed that the BTK inhibitor ibrutinib achieved response rate and
CR of 77% and 33%, respectively [71].
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Figure 3. Canonical and alternative NF-κB signaling pathways. Canonical pathway is triggered by
toll-like receptors (TLRs), pro-inflammatory cytokines such as IL1 and TNFα receptor, and CD40.
It relies on inducible degradation of IκBs, particularly IκBα, leading to nuclear translocation of various
NF-κB complexes, predominantly the p50/RelA dimer. Non-canonical NF-κB pathway relies on
phosphorylation-induced p100 processing, which is triggered by signals from a subset of tumor necrosis
factor α (TNFα) receptor (TNFR) members. This pathway is dependent on NF-κB-inducing kinase
(NIK) and IκB kinase (IKK)α and mediates the activation of RelB/p52 complexes. Proteins potentially
mutated in MCL are highlighted with a yellow star.
2.4.2. NF-κB Signaling
BCR signaling is found activated simultaneously with canonical or non-canonical NF-κB signaling
pathways (these are mutually exclusive) in MCL malignant B cells as well as in different components
of the TME (Figure 3) [72]. After formation of the signalosome, the phosphorylation of CARD11 by
PKCβ allows the formation of the CBM complex containing the BCL10 and MALT (mucosa-associated
lymphoid tissue) adaptors (Figure 3). Once the CBM is formed, the IκB kinase (IKK) complex is
activated and can phosphorylate NF-κB-inhibitor alpha (IκBα), allowing to the ubiquitylation of this
latest and to its degradation by the UPS. Consequently, p50 and RELA transcription factors are released
and translocated to the nucleus where they can control gene transcription (Figure 3). The non-canonical
NF-κB pathway is triggered by the activation of tumor necrosis factor α (TNFα) receptor (TNFR), B-cell
activating factor receptor (BAFFR), and CD40 signaling (Figure 3) [73]. Non-canonical NF-κB signaling
leads to the release of p52 and RELB transcription factors (Figure 3) [72]. This pathway depends
on the degradation of the p100 precursor and NIK (NF-κB-inducing kinase). When this alternative
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pathway is inactive, NIK is constantly degraded through the E3 ubiquitin ligase activity of TRAF3 in
complex with TRAF2 and cellular apoptosis inhibitors (cIAP1/2). As mentioned previously, recurrent
mutations of TRAF2 and BIRC3, two negative regulators of NIK, have been found in 15% of MCL [54].
Thus, constitutive activation of the non-canonical NF-κB pathway in the corresponding patients may
identify an MCL subgroup potentially responsive to NIK inhibitors.
2.4.3. TLR Signaling
Different TLRs have been found overexpressed in MCL cells, suggesting that their signaling may
be particularly relevant for MCL pathogenesis and tumor progression [74,75]. Binding of TLRs by their
cognate ligands triggers the activation of NF-κB (Figure 3), ERK1/2, and AKT pathways, leads to an
upregulation of cyclin D1, and consequent enhanced proliferation. Suggesting a functional cross-talk
between BCR and TLR signaling, a high level of TLR was associated with a hyper-responsiveness of
the BCR machinery and an enhanced expression of genes associated with the NF-κB pathway in MCL
cells [76].
2.4.4. PI3K/AKT/mTOR Signaling Pathway
Chronic activation of the PI3K/AKT signaling axis has been found in approximatively one
third of patients with classical MCL, while 100% of the blastic/blastoid cases analyzed showed
a constitutive activating phosphorylation of AKT at Ser-473 residue. One possible mechanism of
activation identified was a loss of the PTEN (Phosphatase and TENsin homolog deleted on chromosome
10) tumor suppressor [77,78]. Beside this genetic loss of PTEN, both chronic, BTK-mediated,
and ligand-independent, tonic, BCR signaling can activate PI3K (Figure 2) [64]. Finally, ROR1,
a tyrosine kinase-like orphan receptor highly expressed in MCL, binds to CD19 and this complex can
activate PI3K/AKT as well as MEK/ERK1/2 pathways [79].
3. Molecular Mechanisms of Resistance to Standard/Current Therapeutics
Such as for most lymphomas, the majority of MCL patients respond to initial therapies but often
relapse due to the development of drug resistance [80]. Although de novo or primary resistance
is mostly carried by gene abnormalities and tumor cells/TME interactions, acquired or secondary
resistance to therapeutic drugs requires the reprogramming of the cells and the reactivation of key
signaling pathways.
3.1. Resistance to BTK and PI3K Inhibitors
As commented above, BCR signaling is constitutively activated in MCL, mediated by activating
phosphorylation of BTK at Tyr-223. However, in some cases, the constitutive phosphorylation affects
BTK downstream effectors like LYN, SYK, and PKCβ kinases (Figure 2) [81]. Supporting the notion that
BTK is indispensable to B-cell and lymphoma survival [82], the targeting of BTK with the irreversible
inhibitor ibrutinib has shown promising responses in R/R MCL. Mechanistically, ibrutinib induces
lymphocytosis and lymph nodes shrinkage, due to the decrease of interactions between tumor cells
and their TME. Nonetheless, almost one-third of MCL patients are resistant to ibrutinib therapy,
and sensitive patients eventually acquire resistance, experiencing a more aggressive disease [26,83,84].
The second FDA-approved BTK inhibitor, acalabrutinib, potentially more “kinase-selective”, showed
durable response in patients with R/R MCL as single agent [85,86]. However, a longer follow-up is
needed to conclude on acalabrutinib efficacy.
Intrinsic resistance to ibrutinib is due, in part, to the activation of the alternative non-canonical
NIK-NF-κB pathway (Figure 3) [54]. In line with this observation, TRAF2 and BIRC3 are found mutated
in ibrutinib-resistant cells [54], leading to NIK accumulation and conferring dependency on this kinase,
that could offer a novel target for therapy for ibrutinib-resistant patients. Mutations of CARD11 have
been also observed in MCL patients at relapse after ibrutinib treatment, albeit at a low frequency
(5%) [55].
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Beside the genetic alterations underlying ibrutinib refractoriness, TME has been shown to mediate
de novo ibrutinib resistance through the secretion of BAFF and the activation of both canonical and
non-canonical NF-kB pathways [87]. By combining kinomic analysis in vitro and in vivo, Zhao and
coworkers recently identified a PI3K/AKT/mTOR-ILK (integrin β1-linked kinase) axis as a central
hub for TME-MCL tumor cell interactions for both innate and acquired resistance. MCL cells can
develop de novo resistance through a dynamic interplay between lymphoma cells and their TME,
mediated by the triggering of BTK, ERK, and AKT activation and enhanced survival through the
synthesis of several chemokines and cytokines, including BAFF. Then, cells can acquire another degree
of ibrutinib-resistance through the reprogramming of their kinome, the enhanced expression of integrin
β1, and the activation of an integrin β1/ILK (integrin-linked kinase) pathway. Interestingly, integrin β1
can form a complex with ILK and mTORC2, generating a positive loop of activation [88].
Despite these different hypotheses, resistance mechanisms may be more complex since ascribed to
mutations and/or adaptive mechanisms such as activation of alternative pathway or reprogramming of
cell cycle [57,89]. As commented previously, ibrutinib targets irreversibly the BTK, through its ability to
bind a cysteine residue (C481). A missense (C481S) point mutation at the ibrutinib binding site confers
resistance by preventing drug binding [57,90]. In parallel, BTK, ATM, and TP53 mutations were also
recorded for MCL patients who discontinued ibrutinib and developed blastoid transformation [91].
Among PI3K proteins, the isoform p110δ is expressed uniquely on hematopoietic cells. Given
the constitutive activation of the PI3K/AKT/mTOR in MCL, the targeting of p110δ has been explored
mediated by a specific inhibitor, idelalisib. However, the loss of PTEN or the amplification of the
PI3K catalytic subunit p110α [77], impair full idelalisib activity [92–94]. Importantly, the blockade of
p110α enhances the expression of activation-induced cytidine deaminase (AID) and increases somatic
mutation and chromosomal translocation frequency and, in turn, genomic instability. The same
observation was made although, to a lesser extent, with ibrutinib [95]. Given that ibrutinib is currently
being used for the treatment of R/R MCL patients, these data may question its administration for
long periods.
Large-scale genomic studies have identified a hotspot for recurring somatic mutations in exon
1 of CCND1 [42,43]. The most frequent mutations (E36K, Y44D, and C47S) lead to modifications of the
C-terminal part of cyclin D1 and accumulation of the protein through a defective proteolysis by the
UPS. Moreover, those CCND1 mutations contribute to ibrutinib resistance although this mechanism is
still unknown [46]. Importantly, among the downstream targets of PI3K/AKT are the catalytic partners
of cyclin D1, CDK4 and CDK6, the inhibition of which can modify MCL cell cycle and reprogram the
cells toward a re-sensitization to p110δ inhibition [57].
Recently, it has been shown in preclinical models that a paradoxical metabolic reprogramming
toward oxidative phosphorylation (OXPHOS) can confer ibrutinib resistance [96]. The comparison
of ibrutinib-sensitive and -resistant tumor cells by RNA-Seq indicated that differentially expressed
genes were related to glycolytic metabolism, tricarboxylic acid cycle, and glutamine transport.
The upregulation of MYC and mTORC1 reprograms the metabolism toward OXPHOS by activating
genes involved in glycolysis, glutaminolysis, and mitochondrial biogenesis. The upstream effectors of
MYC and mTORC1 activation are not known but could be related to cell cycle dysfunctions [96].
Considering the interplay between the PI3K/AKT and BCR signaling pathways (Figure 2) together
with the hyperactivation of the PI3K/AKT pathway in cases resistant to BTK inhibitors, combination
therapies based on the capacity of p110α inhibition to overcome TME-induced ibrutinib resistance [97],
have been tested with some success in preclinical settings [98].
3.2. Resistance to Bortezomib and Proteasome Inhibitors
Over the past years, proteasome inhibition has been demonstrated to be an effective therapeutic
strategy in MCL. BTZ was the first proteasome inhibitor (PI) approved by the FDA in 2006 as a
second-line treatment for MCL patients. However, more than half of patients are either de novo
resistant or develop secondary BTZ resistance along the course of the treatment [99]. The development
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of new generation PIs such as carfilzomib (CFZ) and ixazomib has not completely solved the problem
of resistance. We have previously reviewed in details the mechanisms of BTZ resistance in MCL and
multiple myeloma [100]. We will focus here on the more prominent aspects of both de novo and
secondary PI resistance.
In MCL cells, BTZ innate resistance has been linked to the accumulation of the anti-apoptotic
protein MCL-1 [101] and/or to the constitutive activation of the NF-κB signaling pathway [102].
In this last study, NF-κB activation was consequent to a proteasome-independent degradation of IκBα
(Figure 3) [102]. The accumulation of the serine/threonine kinase casein kinase 2 (CK2), acting both on
NF-κB and signal transducer and activator of transcription 3 (STAT3) survival pathways contributes
also to BTZ resistance [103]. The redox status has also been reported as a crucial mediator of BTZ
efficacy. Indeed, BTZ induces the generation of reactive oxygen species and the upregulation of the
pro-apoptotic NOXA protein [104]. The upregulation of NOXA is impaired in BTZ-resistant MCL
cells, with a major role of nuclear factor NF-E2 p45-related factor 2 (NRF2) in this phenomenon [105].
BTZ-sensitive MCL cells display an increase in the expression of NRF2 target genes upon treatment
with the drug, whereas resistant cells show minimal variations in this gene signature. Accordingly,
an elevated expression of NRF2 target genes at the basal level, predicts a poor sensitivity to PIs [105].
Among the aberrantly activated pathways in MCL, canonical Wnt signaling has been associated with
the expression of the zinc finger E-box binding homeobox 1 (ZEB1) transcription factor, responsible for
the activation of proliferation-associated genes such as CCND1, MYC, and MKI67 and anti-apoptotic
genes, including MCL1 and BCL2 [106,107]. In turn, ZEB1 level may be considered as a predictive
biomarker of BTZ response.
Secondary BTZ resistance results from successive steps along the evolution of the disease and is
obviously multifactorial. The activation of the UPR (unfolded protein response) and ER (endoplasmic
reticulum) stress pathways in MCL cells exposed to BTZ is required to elicit NOXA transcription [108],
and defective UPR regulation consequent to the overexpression of the ER chaperone protein, BiP,
is associated with both innate and acquired refractoriness to BTZ [109]. In MCL cells, BTZ leads to the
intracellular accumulation of both anti-apoptotic MCL-1 and BH3-only protein, NOXA. By interacting
with MCL-1, NOXA allows the release of the pro-apoptotic effector, BAK, leading to mitochondrial
depolarization and initiation of the apoptotic cascade [101]. Interestingly, the inhibition of cyclin
D1/CDK4 activity in MCL cells reduces the stabilization of NOXA, directing the protein through
degradation by an autophagy mechanism [110].
Resistance to BTZ has also been associated with plasmacytic differentiation of MCL cells. Using
BTZ-adapted cell lines, Pérez-Galán and coworkers showed that these cells express some plasmacytic
features including interferon regulatory factor 4 (IRF4) upregulation as well as CD38 and CD138
expression, but not other B-cell differentiation hallmarks such as Ig secretion or X-box-binding protein
1 (XBP1) splicing [99]. Further studies associated this phenotype with an increased tumorigenicity
of MCL cells in in vivo settings [111]. Interestingly, SOX11, which is overexpressed in a majority of
MCL cells, is the master regulator for the shift of a mature B-cell into a plasmacytic phenotype [112].
The silencing of SOX11 downregulates PAX5, induces BLIMP1, upregulates IRF4 and promotes B-cell
differentiation. Of note, BLIMP1 is also a mediator of NOXA-induced apoptosis in MCL and is required
for BTZ-induced apoptosis in MCL cell lines and primary samples [113].
3.3. Resistance to Lenalidomide
As previously commented, lenalidomide has shown some efficacy in R/R MCL patients including
those resistant to BTZ [25,114,115]. The antitumor activity of lenalidomide and other IMiDs is mediated
through their direct effects on the immune cells (T and NK cells) present in the TME, on the TME itself
by modulating inflammatory cytokines, and by indirect effects on malignant B cells. In particular,
preclinical studies have shown that lenalidomide enhanced NK cell-mediated cytotoxicity against
MCL cells, by promoting the formation of lytic immunological synapses and the secretion of granzyme
B [116,117]. Nonetheless, lenalidomide also interacts with the E3 ubiquitin ligase cereblon (CRBN)
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expressed in MCL patients, and enhances its activity to degrade zinc-finger transcription factors IKZF1
(Ikaros) and IKZF2 (Aiolos), and to decrease IFR4 activity [118]. As detailed before, the hyperactivation
of the IRF4/MYC axis is associated with BTZ resistance. In turn, lenalidomide cooperates with the BET
bromodomain inhibitor CPI203, an indirect inhibitor of MYC transcriptional program, to overcome BTZ
resistance [111]. Associated with dexamethasone, lenalidomide can also target STAT3 and PI3K/AKT
pathways, both indirectly involved in BTZ resistance [119]. Upon lenalidomide treatment, cyclin
D1, as a downstream target of these two pathways, is downregulated and dissociated from the CDK
inhibitor, p27KIP1, and may thus account for this sensitizing effect of lenalidomide [120]. Despite these
advances, the intrinsic mechanisms of lenalidomide resistance in MCL remain only partially known.
Among described mechanisms are the upregulation of MCL-1, the downregulation of BAX, and the
activation of PI3K/AKT signaling pathway consequently to the interference of the hypoxic TME with
NK cell-mediated cytotoxicity [121]. These potential mechanisms are supported by genetic alterations
affecting the corresponding genes in MCL [122].
3.4. Resistance to Temsirolimus and mTOR Inhibitors
As illustrated in Figure 2, mTOR is hyperactivated due to the constitutive activation of PI3K/AKT
in MCL samples. In turn, the use of temsirolimus or everolimus was rapidly seen was a promising
therapeutic option. The treatment of MCL cells with everolimus leads to a rapid dephosphorylation
of mTOR and of two of its downstream targets, p70S6 kinase and eIF4E-binding protein (4E-BP1),
both involved in the regulation of protein translation. However, in vitro experiments showed that,
after a prolonged inactivation of mTOR by everolimus, AKT can be re-phosphorylated in a subset of
cells, counteracting the effects of the drug [123]. The lack of everolimus activity is also linked to the
recruitment of autophagy through an enhanced LC3 (microtubule-associated protein 1A/1B-light chain
3) activity and the accumulation of autophagosomes [122]. This observation raised the possibility that
blocking autophagosome formation could restore everolimus-sensitivity. Temsirolimus, another mTOR
inhibitor was shown to be active in R/R MCL patients, in particular in combination with ibrutinib
treatment [80].
3.5. Resistance to BCL2-Targeting Agents
Among the different genetic lesions sustaining the tumorigenesis of MCL cells, abnormalities
of different apoptosis signaling effectors have been documented. Among them, deletion of BCL2L11
encoding the pro-apoptotic BIM protein, and amplification of the 18q21 locus leading to the
overexpression of BCL-2, have been detected in MCL patients [59]. Importantly, homozygous
deletion of BIM is mainly observed in MCL cell lines, and the loss of BIM protein found in about one
third of MCL patients [124], is unlikely to be explained by the infrequent, heterozygous deletion of the
gene reported by Tagawa and coworkers [125], and even not confirmed by others [126]. In this context,
venetoclax (ABT-199), a BH3 mimetic with high specificity for BCL-2, has demonstrated notable activity
as monotherapy in MCL patients [36]. By generating venetoclax-resistant cell lines, Tahir and coworkers
described a variety of mechanisms conferring resistance, including the upregulation of MCL-1 or
BCL-XL anti-apoptotic proteins, and downregulation of the pro-apoptotic BIM and BAX [127].
Among the possible mechanism at the origin of BCL-2 overexpression, the E3 ubiquitin ligase,
F-box only protein 10 (FBXO10), that targets BCL-2 for UPS-mediated degradation, is downregulated in
MCL tumor cells. Thus, FBXO10 downregulation and BTK-mediated activation of the NF-κB canonical
pathway may cooperate to sustain BCL-2 upregulation [128]. In turn, the targeting of BCL-2 in
combination with pharmacological blockade of NF-κB has been tested in preclinical settings, showing
synergy despite the onset of acquired resistance.
In parallel, by using MCL primary samples in vitro or engrafted in vivo (PDX), Zhao and coworkers
reported that venetoclax drives the selection of clones having lost or a reduced copy number of the
18q21 amplicon that harbors BCL-2 [129]. Moreover, the reprogramming of super enhancer-driven
transcription contributes to venetoclax resistance.
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Finally, while analyzing the genetic determinants of the effectivity of the ibrutinib-venetoclax
combination, Agarwal and colleagues found that all patients exhibiting alterations of ATM achieved
a CR. By contrast, patients with deletion of the chromosome 9p21 that includes CDKN2A/B locus,
and mutations in components of the SWI/SNF chromatin-remodeling complex, were resistant to or
relapsed shortly after this therapy [130]. The analyses of circulating tumor DNA further showed that
compromised SWI/SNF complex facilitated BCL2L1 transcription and the upregulation of BCLXL.
4. Combination Therapies as Strategies to Overcome Drug Resistance
With the possible exception of ibrutinib, it seems unlikely that the biological drugs approved for
the treatment of R/R patients will be used as single agents outside of maintenance strategies. They may
rather have a role as part of combination therapy [131]. In this sense, several clinical trials are ongoing
with different combinations such as temsirolimus plus rituximab (ORR 60%; 19% CR), bortezomib
with R-HyperCVAD (95% CR) or lenalidomide plus rituximab (ORR 92%; 64% CR) [132,133]. Active
ongoing trials combining new biological agents in R/R MCL patients are gathered in Table 2.
Table 2. Active clinical trials combining new biological agents in R/R MCL.
Drug Combination Targets Study Number Efficiency
Obinutuzumab + Venetoclax + Ibrutinib CD20, BCL2, BTK NCT02558816 No results available
Ibrutinib + Lenalidomide + Rituximab BTK, CRBN/CD20 NCT02446236 No results available
Alisertib + Bortezomib + Rituximab Aurora A kinase, 20Sproteasome, CD20 NCT01695941 No results available
Ibrutinib + Bortezomib BTK, 20S proteasome NCT02356458 No results available
Rituximab + Bendamustine + Ibrutinib CD20, alkylating agent, BTK NCT01479842 No results available
Lenalidomide + Ibrutinib CRBN, BTK NCT01955499 No results available
BKM120 + Rituximab PI3K, CD20 NCT02049541 No results available
Entospletinib + Obinutuzumab SYK, CD20 NCT03010358 No results available
Everolimus + Lenalidomide mTOR, CRBN NCT01075321 9.8% CR, 19.5% PR, 39%SD, 29.3% progression
Abbreviations: complete response (CR), partial response (PR), stable disease (SD).
4.1. Targeting of Environmental Factors
4.1.1. BCR Signaling
In order to increase the response to ibrutinib, this latest has been combined with rituximab,
bendamustine, and R-CHOP in both untreated and refractory MCL cases [134–136]. In relapsed setting,
ibrutinib/rituximab-based treatments resulted in higher responses, with ORR and CR of 88% and 44%,
respectively. In combination with bendamustine and rituximab, the ORR was 94%, including 76% CR.
Early phase study of the BTK inhibitor in combination with R-CHOP in previously untreated patients
showed ORR of 94% with some manageable toxicity. Recently, combination of ibrutinib and venetoclax
in R/R MCL showed ORR of 71% after 16 weeks of treatment. Most patients (67%) were negative for
minimal residual disease (MRD) as assessed by flow cytometry [137].
4.1.2. Adhesion Molecules
The capacity of MCL cells to reach and to colonize extranodal tissues is considered to depend on
their transient interaction with vascular endothelium cells through adhesion molecules like selectins
and integrins (“rolling”), and to migrate through the endothelium after chemokine receptor activation
(“homing”), two processes that are conserved between most malignant B cells and their normal
counterparts [138]. However, despite the pattern of early dissemination in MCL, only a few studies
have investigated the expression and function of adhesion molecules and chemokine receptors related
to these processes. Among them, high levels of functional C-X-C chemokine receptor type 4 (CXCR4)
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and 5 (CXCR5) and VLA-4 have been reported in MCL cell lines and primary cells. In agreement with
an important role of these molecules in the migratory process of MCL cells and for MCL–stromal cell
interactions and pseudo-emperipolesis [139], the CXCR4 antagonist plerixafor and the anti-VLA-4
antibody natalizumab have been shown to efficiently block CXCR4 and VLA-4 in in vitro and in vivo
models of MCL, thus impeding physical interactions between MCL cells and MSCs, and rending these
mobilized MCL cells more susceptible to standard therapies [140].
4.1.3. IMiDs
While thalidomide has proved to be effective in R/R MCL patients as a single agent [141],
in relapsed MCL patients, thalidomide-rituximab combination reached a ORR of 81% and a PFS of
20 months [142]. Another combination study of lenalidomide with rituximab has shown promising
ORR in MCL patients with a poor response to initial treatment [143]. When used at frontline, beside the
significant clinical benefit of this combination, a higher incidence of non-invasive skin and pancreatic
cancers were reported [132]. At 5 years, 61% evaluable patients had remained in remission. Median
PFS was not reached but estimated at 3 and 4 years, OS rates were 80.3% and 69.7%, respectively,
thus confirming that combination therapy of lenalidomide with rituximab in first-line setting can result
in long-term remission in MCL patients [144].
Regarding the combination of the IMiD with BTZ, preliminary results gathered in in vitro and
in vivo models of BTZ-resistant MCL suggested that lenalidomide could partially overcome the
resistance to the proteasome inhibitor mediated by the downregulation of IRF4 and MYC [111].
However, when lenalidomide and BTZ combination was administered to R/R patients for induction
and maintenance therapy, outcomes were not satisfactory with median PFS and OS of 7 and 26 months,
respectively, and ORR and CR of 39.6% and 15.1%, respectively [145]. These disappointing results
were thought to be due to lenalidomide toxicity and inadequate dosing.
The efficacy of combining lenalidomide was also evaluated as upfront treatment in elderly patients
(>70 years), with bendamustine and rituximab. After completion of induction therapy, 64% patients
had CR and 36% were minimal residual disease (MRD) negative. Median PFS and OS were 42 and
53 months, respectively [146]. A major limitation of this combination was high incidence of serious
infections, which makes this treatment probably inadequate for elderly patients.
4.2. New Therapeutics Antibodies
Despite the remarkable clinical efficacy of rituximab, a significant proportion of MCL patients
experience disease relapse after a first step of clinical remission. To overcome resistance to
rituximab-based regimens, a number of second generation anti-CD20 mAbs have been developed.
Among these antibodies, ofatumumab is a fully human mAb that binds to an epitope encompassing both
small and large loops of the extracellular domain of CD20. This binding epitope, distinct from that of
rituximab, resides more proximal to the cell membrane. When compared with rituximab, ofatumumab
exhibited enhanced CDC activity in a panel of MCL cell lines and prolonged survival in a mouse model
of MCL. Importantly, significant activity of ofatumumab was observed in rituximab-resistant cases
characterized by low levels of CD20 and/or high expression of complement inhibitory proteins [147].
However, first results with this Ab, in R/R MCL were disappointing in both single agent and combination
settings [34].
Obinutuzumab (GA101), a type II glycol-engineered, humanized, anti-CD20 Ab was designed
in an attempt to overcome common mechanisms of resistance to rituximab. To that aim, this Ab has
non-fucosylated sugars on the Fc portion, associated with a more potent effector response, and has
also the ability to cause homotypic adhesion, triggering a different mechanism of direct cell death
(DCD) [148]. This antibody, previously approved in frontline and R/R follicular lymphoma and
with known efficacy in preclinical models of MCL [149], has demonstrated its utility in clinical
settings when combined with either venetoclax frontline therapy in untreated MCL (LYMA-1001
trial) [150], or in combination with ibrutinib and/or venetoclax in relapsed settings (OAsIs trial). In this
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second trial, both obinutuzumab-ibrutinib and obinutuzumab-ibrutinib-venetoclax combinations were
well-tolerated and provided high disease control including CR at the molecular level (i.e., without
detectable CCND1 transcript) [151]. In the same line, obinutuzumab-venetoclax combination has also
recently been suggested as a possible salvage therapy in nnMCL. Of special interest, this combination
was well-tolerated and induced a CR after only two cycles and in a patient with prior refractoriness to
bendamustine and ibrutinib [152].
A third new generation glycol-engineered anti-CD20 mAb, ublituximab (TG-1101) was engineered
to have a low fucose content, conferring it enhanced ADCC activity when compared to rituximab,
especially in rituximab-resistant cases with low expression of CD20. This Ab was well-tolerated and
highly active in combination with ibrutinib in patients with R/R MCL [153]. In this phase 2 trial,
among the 15 patients tested, a 87% ORR, including 33% CR, was reported, slightly superior to the 46%
ORR and 17% CR observed in another cohort of R/R B-NHL when associating ublituximab to another
inhibitor of PI3Kδ, umbralisib (U2 regimen) [154]. From a mechanistic point of view, first preclinical
studies in MCL and other B-NHL cells co-cultured with stromal cells and macrophages, suggested that
the U2 combination may cooperate with the blocking of the CD47 immune checkpoint by regulating
genes related with cell architecture [154].
The membrane antigen CD74, that functions as a MHC class II chaperone, has been implicated in
malignant B-cell growth and survival, making it a potential target for immunotherapy. The humanized
version of the anti-CD74 mAb LL1, milatuzumab, exerts a direct tumoricidal effect in a disseminated
mouse model of Burkitt lymphoma with a mechanism of action distinct from antibody-dependent
cell-mediated cytotoxicity (ADCC) or CDC [155]. Of interest, therefore, it has been tested with success
in preclinical model of MCL in combination with anti-CD20 mAb [156].
Bispecific T cell-engaging (BiTE) therapy consists of the transient engagement of CD3+ polyclonal
T cells with malignant CD19+ B cells, resulting in T-cell-mediated, granzymes- and perforin-dependent
lysis of tumor cells, and concomitant T-cell expansion and release of cytokines. In a phase 1 trial for
heavily pretreated B-NHL patients including 24 MCL patients, the bispecific CD19/CD3 antibody
blinatumomab showed a remarkable single agent activity with an ORR of 71% [157]. However,
the shortness of the observed response was associated with the inability of blinatumomab to recruit
competent cytotoxic T cells, leading to premature T-cell exhaustion. Thalidomide derivatives like
lenalidomide have been shown to improve efficacy of anti-CD20 mAb (rituximab) through T and NK
cell activation even in patients with previous relapse after rituximab-based therapy [143]. Based on this
observation, the blinatumomab/lenalidomide combination regimen was evaluated in a phase 1 trial
involving patients with R/R CD19+ B-NHL, including 3/18 MCL patients. At the median follow-up,
combination-receiving patients achieved a 83% ORR, including 50% of CR, with a median PFS of
8.3 months, thus demonstrating the safety and the efficacy of this regimen in previously heavily treated
patients [158].
4.3. Epigenetic Drugs
With the recent use of NGS technologies for the identification of lymphoma mutational landscape,
it came out that different epigenetic deregulations were associated with B lymphomagenesis and
lymphoma progression [159]. However, targeting epigenetic modification mechanisms is a relatively
novel approach in MCL. Most of the preclinical studies have been centered on the evaluation of HDAC
inhibitors, vorinostat being the main agent included in combination regimens with either proteasome,
PI3K-AKT, CDK or BTK inhibitors [160]. From these different strategies, the combination of vorinostat
plus BTZ has been evaluated in a phase 2 trial, but only a modest clinical activity was observed [161].
More recently, some bromodomain inhibitors with the capacity to targeting epigenetic readers of
the BRD family, have been shown to synergistically induce apoptosis when combined to venetoclax,
palbociclib, or panobinostat, in BTK wild-type, ibrutinib-resistant MCL cell lines characterized by the
overexpression of antiapoptotic molecules like BCL-2, BCL-XL, XIAP, or with increased levels of CDK6
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or AKT [162]. These promising results thus warrant the clinical evaluation of bromodomain inhibitors
with other biological agents in R/R MCL patients.
Beside HDAC and bromodomain inhibition, cladribine, a hypomethylating agent that indirectly
downregulates DNA methylation, has been used with vorinostat and rituximab in a phase 1/2 trial
involving both naïve and R/R MCL patients. This triple combination reached an ORR of 97%, including
80% CR, with a 2-year PFS of 70.7% and OS of 86.9%, in previously untreated MCL patients. However,
the ORR dropped to 39% in R/R MCL patients [163]. Improved results were reported in another
trial using cladribine-rituximab combination in association with BTZ in B-NHL patients, including
24 MCL cases: the ORR and CR for both new and relapsed/refractory MCL cases were 85% and
77%, respectively [164]. Thus, although hypomethylating agent might show reduced single activity
in R/R MCL patients, these last results warrant the evaluation of cladribine-rituximab backbone in
further trials to determine whether the activity of this combination can be improved by the inclusion of
additional biological agents.
4.4. Immune Checkpoint Inhibitors
Different immune checkpoint molecules expressed at the surface of tumor cells and accompanying
immune cells, have been recently involved in the lowering of antitumor immunity. The main players
are programmed death 1 (PD-1) and its ligands PD-L1 and PD-L2, cytotoxic T-lymphocyte activator
4 (CTLA-4), lymphocyte activation gene 3 (LAG-3), and CD200. MCL B cells were recently shown
to express PD-1, PD-L1, and some degree of CD200 [165]. Accompanying T and NK cells (immune
effectors), were positive for PD-1. PD-L1 expression on MCL cells inhibits T cell-mediated tumor
cytotoxicity and their specific antitumor response. Indeed, in the presence of T cells, MCL cells
increased their surface levels of PD-L1 in an IFNγ- and CD40-dependent manner. Despite initial
in vitro and in vivo evidence for PD-L1 inhibition as a mechanism for effective enhancement of the
T-cell response and T-cell-mediated killing of primary cells from PD-L1+ MCL patients, early clinical
studies have not validated this approach as a successful strategy to treat patients with MCL [166].
However, as PD-L1 upregulation observed in MCL-T cell cocultures could be counteracted by either
BTK or PI3K inhibition using ibrutinib or duvelisib [165], the combination of PD-1 blockade with BCR
pathway inhibitors could represent a very promising combination [167].
Another immune checkpoint of interest in MCL is CD47. This myeloid checkpoint acts as a
“don’t-eat-me” signal to macrophages and is found upregulated by tumor cells to evade the host’s
immune response. ALX148 is a fusion protein comprised of a high affinity CD47 blocker linked to an
inactive human Ig Fc region. This agent has been shown to increase the efficacy of the anti-CD20 mAbs
rituximab and obinutuzumab in xenograft models of hematologic malignancies, bridging innate and
adaptive immune responses including the activation of dendritic cells and a shift of tumor associated
macrophages toward a pro-inflammatory phenotype [168]. In a phase 1 trial, a total of 20 CD20+
B-NHL patients, including four R/R MCL, received ALX148 in combination with rituximab. A 31%
ORR was achieved in the most aggressive B-NHL cases, including DLBCL and MCL patients, with two
MCL patients achieving a PR. ALX148 demonstrated excellent tolerability with favorable PK/PD
characteristics and with unreached maximum tolerated dose [169].
As commented previously, T-cell exhaustion plays a major role in immune evasion in B-NHL,
including MCL. CD27 is a co-stimulatory receptor involved in the negative regulation of T-cell activation
following TCR engagement. Varlilumab (CDX-1127) is an agonistic IgG1 mAb that can bind CD27
and reverse the mechanism of T-cell exhaustion, allowing direct anti-tumoral activity in xenograft
models of human lymphoma via ADCC [170]. Following previous phase 1 data supporting the safety
and tolerability of single-agent varlilumab in advanced hematologic malignancies (ClinicalTrials.gov
Identifier: NCT01460134), a randomized phase 2 study is currently ongoing, evaluating whether the
varlimumab-mediated CD27 activation could synergize with the anti-PD-1 antibody, nivolumab, in R/R
aggressive B-cell lymphomas, including MCL [171].
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Another activation-induced costimulatory molecule with an important role in the regulation of
immune responses is 4-1BB (CD137; TNFRS9). Validating the relevance of blocking 4-1BB or its natural
ligand, 4-1BBL, in cancer, it has been shown that 4-1BB-mediated anti-cancer effects are based on
its ability to facilitate the activation of cytotoxic T lymphocytes (CTL) and the production of IFN-γ.
Accordingly, specific 4-1BB/CD137 agonistic antibodies can trigger costimulatory signals that enhance
ADCC and elicit T-cell-mediated antitumor immune responses. A phase 1 study evaluated the activity
of the anti-4-1BB antibody utomilumab in combination with rituximab in a total of 67 patients with
CD20+ R/R B-NHL, including six MCL patients. The best overall response (BOR), including CR or
PR, was observed in patients with MCL, FL, and DLBCL, with a favorable safety profile and clinical
activity [172].
5. Conclusions
The main challenges in the management of MCL patients are tightly correlated with the biological
diversity of the disease and its heterogeneous clinical presentation, that both underlie the existence
of various morphological subtypes, distinct IGHV and TP53 mutational status, together with the
absence of actionable genetic variants that could define a common therapeutically amenable target
for this disease. With standard chemotherapeutic regimens, physicians have to face frequent disease
progression, recurrence, and limited disease-free interval. Among the above-mentioned therapies,
intensified chemotherapy associated to rituximab or lenalidomide could allow better control of the
disease in treatment-naïve patients; however those treatments that can converge to the blockade of BCR
and NF-kB signal pathways (ibrutinib, everolimus) and/or to the impairment of apoptotic signaling
(venetoclax), seemed to have the best therapeutic significance in the management of R/R patients.
New biological agents or novel rationally based drug combinations including immunotherapeutic
antibodies or CAR T-cell therapy will hopefully lead not only to better control of the disease, but also
to the effective eradication of the residual clone. Finally, in an effort to achieve long-term remission
without excessive toxicity, it is a safe bet that the development of genome-based precision medicine
based on the last technological advances and on our growing knowledge on MCL biology will be the
way to go.
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